

S4 Table. Ranking of the onset and resolution of grade ≥ 3 immune-related adverse events caused by nivolumab, ipilimumab, and nivolumab plus ipilimumab

Adverse events	Ranking of Onset			Ranking of Resolution		
	1	2	3	1	2	3
All categories	IPI (7.4) ^a	NIV+IPI (7.9) ^b	NIV (27.5) ^a ^b	IPI (3.7)	NIV+IPI (4.0) ^b	NIV (5.1) ^b
Skin	IPI (4.6)	NIV+IPI (6.3)	NIV (23.0)	NIV+IPI (3.3) ^c	IPI (6.4) ^c	NIV (6.6)
Gastrointestinal	IPI (7.0) ^a	NIV+IPI (7.4) ^b	NIV (36.4) ^a ^b	NIV (3.0)	IPI (3.1)	NIV+IPI (3.2)
Hepatic	NIV+IPI (7.9) ^c	IPI (9.9) ^c	NIV (14.1)	IPI (3.7)	NIV+IPI (4.0)	NIV (5.1)
Endocrine	IPI (10.6) ^a	NIV+IPI (12.2) ^b	NIV (24.0) ^a ^b	NIV+IPI (11.6) ^b ^c	NIV (52.6) ^b	IPI (72.1) ^c
Pulmonary	NIV+IPI (6.0) ^b	IPI (6.2) ^a	NIV (27.5) ^a ^b	NIV+IPI (1.5) ^b ^c	NIV (5.9) ^b	IPI (6.3) ^c
Renal	IPI (10.0) ^a	NIV+IPI (11.3) ^b	NIV (123.4) ^a ^b	NIV+IPI (2.4) ^b	IPI (4.6)	NIV (7.9) ^b
Hypersensitivity/ Infusion reaction	IPI (7.4)	NIV (22.9)		NIV (0.2) ^a	IPI (0.3) ^a	

The number in parentheses of represents the pooled median time (weeks). The ranking is arranged from the shortest to the longest pooled median time. IPI, ipilimumab; NIV, nivolumab. ^ap < 0.05 between the comparison of NIV and IPI, ^bp < 0.05 between the comparison of NIV and NIV+IPI, ^cp < 0.05 between the comparison of IPI and NIV+IPI.